Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.
Latest From Joseph Haas
Genfit CEO Pascal Prigent talks to Scrip about the company's high-profile trial failure in NASH and the pipeline pivot to various other drug candidates for rare liver diseases.
Emerging Company Profile: Mini-proteins offer some of the capabilities of small molecules and antibodies with fewer limitations, Ordaõs claims. The biotech wants to lead a paradigm shift from discovery to design.
After not closing a deal this year on Seagen, Merck takes a smaller step with a $1.35bn bid for Imago and its candidate for multiple myeloproliferative neoplasm indications.
Two clinical-stage vaccine candidates for Lassa Fever and MERS, funded by CEPI, are being discontinued, but Inovio will continue its focus on DNA medicines for HPV-related conditions and cancer.
Plus deals involving Dong-A/Polifarma, Intas/Syna, Kissei/Synmosa, Ono/Memo, Takeda/Shionogi, Fosun/Lilly and JW Therapeutics/2seventy bio.
Former Novartis executive and venture capitalist David Epstein will step in to lead Seagen after its founder resigned in a scandal and amid M&A speculation.